Mechanisms of Cisplatin-Induced Ototoxicity and Prevention

Overview

Journal Semin Hear

Specialty Otorhinolaryngology

Date 2019 May 1

PMID 31036996

Citations 53

Authors

Leonard P Rybak

Debashree Mukherjea

Vickram Ramkumar

Affiliations

Soon will be listed here.

Abstract

Cisplatin is a highly effective antineoplastic agent used to treat solid tumors. Unfortunately, the administration of this drug leads to significant side effects, including ototoxicity, nephrotoxicity, and neurotoxicity. This review addresses the mechanisms of cisplatin-induced ototoxicity and various strategies tested to prevent this distressing adverse effect. The molecular pathways underlying cisplatin ototoxicity are still being investigated. Cisplatin enters targeted cells in the cochlea through the action of several transporters. Once it enters the cochlea, cisplatin is retained for months to years. It can cause DNA damage, inhibit protein synthesis, and generate reactive oxygen species that can lead to inflammation and apoptosis of outer hair cells, resulting in permanent hearing loss. Strategies to prevent cisplatin ototoxicity have utilized antioxidants, transport inhibitors, G-protein receptor agonists, and anti-inflammatory agents. There are no FDA-approved drugs to prevent cisplatin ototoxicity. It is critical that potential protective agents do not interfere with the antitumor efficacy of cisplatin.

Citing Articles

Fasudil protects spiral ganglion neurons and hair cells against cisplatin-induced apoptosis by inhibiting reactive oxygen species accumulation and regulating the ROCK/PTEN/AKT signaling pathway.

Yin P, Jiang Z, Wang X, Gong S, Zhang C, Fan Z Toxicol Res (Camb). 2025; 14(2):tfaf030.

PMID: 40052021 PMC: 11881692. DOI: 10.1093/toxres/tfaf030.

Characterization and Otoprotective Effects of Polysaccharides from .

Banti M, Garcia-Gil M, Guidotti L, Di Giuseppe G, Rapposelli S, Monti D Molecules. 2025; 30(2).

PMID: 39860094 PMC: 11767895. DOI: 10.3390/molecules30020224.

A comprehensive review on alpha-lipoic acid delivery by nanoparticles.

Mosallaei N, Malaekeh-Nikouei A, Sarraf Shirazi S, Behmadi J, Malaekeh-Nikouei B Bioimpacts. 2024; 14(6):30136.

PMID: 39493899 PMC: 11530970. DOI: 10.34172/bi.2024.30136.

Hearing loss during chemotherapy: prevalence, mechanisms, and protection.

Kessler L, Koo C, Richter C, Tan X Am J Cancer Res. 2024; 14(9):4597-4632.

PMID: 39417180 PMC: 11477841. DOI: 10.62347/OKGQ4382.

Reprogramming with , , and promotes hair cell regeneration in the adult organ of Corti.

McGovern M, Ghosh S, Dupuis C, Walters B, Groves A PNAS Nexus. 2024; 3(10):pgae445.

PMID: 39411090 PMC: 11477985. DOI: 10.1093/pnasnexus/pgae445.

References

Planting A, Catimel G, de Mulder P, de Graeff A, Hoppener F, Verweij J . Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol. 1999; 10(6):693-700. DOI: 10.1023/a:1008353505916. View

Alam S, Ikeda K, Oshima T, Suzuki M, Kawase T, Kikuchi T . Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res. 2000; 141(1-2):28-38. DOI: 10.1016/s0378-5955(99)00211-7. View

Rybak L, Husain K, Morris C, Whitworth C, Somani S . Effect of protective agents against cisplatin ototoxicity. Am J Otol. 2000; 21(4):513-20. View

Sluyter S, Klis S, de Groot J, Smoorenburg G . Alterations in the stria vascularis in relation to cisplatin ototoxicity and recovery. Hear Res. 2003; 185(1-2):49-56. DOI: 10.1016/s0378-5955(03)00260-0. View

Fisher M, Lange B, Needle M, Janss A, Shu H, Adamson P . Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004; 43(7):780-4. DOI: 10.1002/pbc.20132. View

Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G . High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope. 2004; 114(9):1660-7. DOI: 10.1097/00005537-200409000-00030. View

Li Y, Womer R, Silber J . Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004; 40(16):2445-51. DOI: 10.1016/j.ejca.2003.08.009. View

Wang J, Ladrech S, Pujol R, Brabet P, van de Water T, Puel J . Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res. 2004; 64(24):9217-24. DOI: 10.1158/0008-5472.CAN-04-1581. View

Khimich D, Nouvian R, Pujol R, Tom Dieck S, Egner A, Gundelfinger E . Hair cell synaptic ribbons are essential for synchronous auditory signalling. Nature. 2005; 434(7035):889-94. DOI: 10.1038/nature03418. View

10.

Lynch E, Gu R, Pierce C, Kil J . Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs. 2005; 16(5):569-79. DOI: 10.1097/00001813-200506000-00013. View

11.

Dickey D, Wu Y, Muldoon L, Neuwelt E . Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005; 314(3):1052-8. DOI: 10.1124/jpet.105.087601. View

12.

van Ruijven M, de Groot J, Klis S, Smoorenburg G . The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005; 205(1-2):241-8. DOI: 10.1016/j.heares.2005.03.023. View

13.

Marina N, Chang K, Malogolowkin M, London W, Frazier A, Womer R . Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005; 104(4):841-7. DOI: 10.1002/cncr.21218. View

14.

Liang F, Schulte B, Qu C, Hu W, Shen Z . Inhibition of the calcium- and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience. 2005; 135(1):263-71. DOI: 10.1016/j.neuroscience.2005.05.055. View

15.

Knight K, Kraemer D, Neuwelt E . Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005; 23(34):8588-96. DOI: 10.1200/JCO.2004.00.5355. View

16.

So H, Kim H, Lee J, Park S, Park C, Kim Y . Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cell Death Differ. 2006; 13(10):1763-75. DOI: 10.1038/sj.cdd.4401863. View

17.

Kushner B, Budnick A, Kramer K, Modak S, Cheung N . Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006; 107(2):417-22. DOI: 10.1002/cncr.22004. View

18.

Coradini P, Cigana L, Selistre S, Rosito L, Brunetto A . Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007; 29(6):355-60. DOI: 10.1097/MPH.0b013e318059c220. View

19.

So H, Kim H, Kim Y, Kim E, Pae H, Chung H . Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1. J Assoc Res Otolaryngol. 2008; 9(3):290-306. PMC: 2538144. DOI: 10.1007/s10162-008-0126-y. View

20.

Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T . Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008; 26(22):3749-55. PMC: 2504739. DOI: 10.1200/JCO.2007.14.3974. View